TICKERNERD
Menu
PRFXPRFXHealthcare · Drug Manufacturers - Specialty & Generic

PRFX Stock Forecast: PRF Technologies Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.86

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap
$3.0M
Ticker Nerd rank
4 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$7.3M
Net income−$7.3M
Free cash flow−$5.0M
Quarterly, 7 quarters to 30 June 2024 · latest quarter's figure shown
Ticker Nerd rank

PRFX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PRF Technologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Accruals
30
Revisions
25
Issuance
23
Momentum
21
Volatility
1
Quality
0
Value
0
Growth
0

Size (98): Smaller than most of the companies we track.

Growth (0): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PRFX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRFX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Oct 2024Maxim GroupDowngradeHold—
26 June 2024Maxim GroupReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRFX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PRFX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

PRF Technologies Ltd. (PRFX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
97.1×

Cheaper than 4% of US stocks

Price / book
0.1×

Cheaper than 91% of US stocks

EV / EBITDA
2.0×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−18114.3%

Higher than 1% of US stocks

Net margin
−311.8%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−45.3%

Higher than 23% of US stocks

Return on assets
−21.9%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

PRF Technologies Ltd. (PRFX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PRF Technologies Ltd. has a market value of $3.0M and an enterprise value of −$8.3M.

  • Revenue in the twelve months to 30 June 2024: $0.0.

  • Net income over the same four quarters: −$17.7M.

  • Free cash flow in the twelve months to 30 June 2024: −$11.4M, after $21K of capital spending.

  • Shares outstanding: 402,628.

  • Trailing P/E: 0.0×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • PRF Technologies Ltd. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2024 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

PRFX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PRFXPRF Technologies Ltd.$3.0M
4
BTAIBioXcel Therapeutics, Inc.$2.3M
—
SHPHShuttle Pharmaceuticals Holdings, Inc.$2.2M
16
APUSApimeds Pharmaceuticals US, Inc.$3.2M
9
SXTCChina Sxt Pharmaceuticals, Inc.$3.4M
11
SBFMSunshine Biopharma, Inc.$4.1M
61
YCBDcbdMD, Inc.$5.4M
28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PRF Technologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRFX news & analysis

PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform

GlobeNewsWire · 9 Sept 2026positive

PRF Technologies announced it will establish GridFeed, its AI-driven renewable energy trading platform, as a standalone subsidiary to pursue strategic investment, partnerships, and commercial collaborations. The platform, built on validated AI technology and existing engagements with renewable energy companies, is scheduled to be showcased at Energy Trading Week Europe in London to over 2,500 energy-market professionals.

Why it matters — A PRFX watcher would care because spinning off GridFeed into a standalone subsidiary could open the door to direct strategic investments and partnerships for a key AI-driven platform.

PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business

GlobeNewsWire · 3 Sept 2026positive

PRF Technologies provided its First Half 2026 business update, highlighting progress across its healthcare and AI energy operations. Key development: the FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery, with patient enrollment expected in the second half of 2026.

Why it matters — The FDA clearance and planned Phase II trial move OcuRing™-K closer to clinical validation in the U.S., marking meaningful pipeline progress for PRFX watchers.

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

GlobeNewsWire · 27 July 2026positive

PRF Technologies' interim CEO Efraim Cohen-Arazi issued a letter to shareholders detailing the company's strengthened financial position, including $10 million in new capital, and provided updates on LayerBio's preparations for a planned Phase 2 clinical trial of OcuRing™-K and DeepSolar's progress toward commercial launch.

Why it matters — The letter updates shareholders on the company's improved financial standing and progress across both its biotechnology and AI-driven energy divisions.

FAQ

Frequently asked questions about PRFX stock

Is PRFX stock a buy right now?

Of the 1 analysts covering PRF Technologies Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PRF Technologies Ltd. 4 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRFX?

As at 12 Sept 2026, PRF Technologies Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the PRFX stock forecast for 2030?

No analyst covering PRF Technologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRFX are extrapolating price history, which says nothing about the business.

What does PRF Technologies Ltd. do?

PRF Technologies Ltd. is a specialty pharmaceutical company focused on reformulating established therapeutics for clinical use.

What is the latest news on PRFX?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform". PRF Technologies announced it will establish GridFeed, its AI-driven renewable energy trading platform, as a standalone subsidiary to pursue strategic investment, partnerships, and commercial collaborations. The platform, built on validated AI technology and existing engagements with renewable energy companies, is scheduled to be showcased at Energy Trading Week Europe in London to over 2,500 energy-market professionals.

Company

About PRF Technologies Ltd.

PRF Technologies Ltd. is a specialty pharmaceutical company focused on reformulating established therapeutics for clinical use. Its current portfolio centers on post-surgical pain management and localized drug-delivery solutions, including PRF-110, an oil-based formulation designed for direct application into the surgical wound bed to provide sustained analgesia, and OcuRing-K, a bio-erodible implant developed for use in cataract surgery. The company operates in the healthcare sector with an emphasis on developing proprietary treatment options that target specific surgical settings and recovery needs. Headquartered in Tel Aviv, Israel, PRF Technologies also maintains activity in advanced drug-delivery technologies, supporting its role as a niche player in specialty therapeutics and perioperative care.

CEO Mr. Efraim Cohen-Arazi · 6 employees · Israel · https://www.painreform.com